ANALYSIS METHOD FOR INCREASING SUSCEPTIBILITY TO SORAFENIB TREATMENT IN HEPATOCELLULAR CARCINOMA

摘要

The present invention provides an analysis method for providing information needed for the diagnosis of hepatocellular carcinoma patients having susceptibility to sorafenib. It was discovered by the present invention that, when the expression levels of eight genes in tumor tissue of a hepatocellular carcinoma patient, i.e., CDH1, CHAD, EFNA2, FANCC, MAP2K1, MEN1, PBRM1, and PPARG genes, are combined and analyzed, a response (susceptibility) to sorafenib can be predicted with high accuracy. Thus, a combination of the genes can be effectively used as a biomarker for selecting hepatocellular carcinoma patients having susceptibility to sorafenib.